CHICAGO — The addition of ribociclib to endocrine therapy significantly improved OS for premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, according to results of the MONALEESA-7 study presented at ASCO Annual Meeting.
The advent of cyclin dependent kinase 4/6 inhibitors has had a dramatic impact on breast cancer treatment, according to Debra Patt, MD, MPH, MBA, executive vice president of Texas Oncology and director of analytics for US Oncology Network and McKesson Specialty Health.
“We have so many patients who take endocrine therapy and CDK 4/6 inhibition and — for many years — we have been about to talk about the PFS benefit, which is nearly triple for patients who receive this unique therapy,” Patt told HemOnc Today. “In the MONALEESA-7 trial ... we not only saw a PFS benefit, as expected, but also an OS benefit. This confirms what we have suspected for a long time.”
Each CDK 4/6 inhibitor — including ribociclib (Kisqali, Novartis), palbociclib (Ibrance, Pfizer) and abemaciclib (Verzenio, Eli Lilly) — have different costs, dosing schedules and toxicities, Patt said.
“But what we’ve seen is that they continue to be clinically meaningful in making advanced breast cancer a chronic disease for many of our patients,” Patt said. — by Mark Leiser
Disclosure: Patt reports no relevant financial disclosures.